Source: Kapitales ResearchHighlights

• TGA approval allows the company to commercially launch its CT:VQ technology across Australia, creating a new growth opportunity.
• Vanguard Group has become a substantial shareholder with a 5.036% stake, representing 29,983,291 ordinary shares.
• CT:VQ continues to broaden its global footprint after securing regulatory approvals in Australia, the United States, the European Union, the United Kingdom, Canada, and New Zealand.

Share Price Climbs as Key Milestones Boost Confidence4DMedical Limited (ASX: 4DX) attracted strong investor interest after its shares rose 3%, taking the stock to a CMP of AU$4.700. The upward move followed a significant regulatory milestone that positions the company to begin commercial sales of its flagship lung imaging technology in Australia. Investor sentiment was further supported after global investment manager Vanguard Group disclosed a substantial holding of 5.036%, equivalent to 29,983,291 ordinary shares, signalling increasing institutional confidence.Regulatory Win Opens the Door to Commercial GrowthThe company has received approval from Australia's Therapeutic Goods Administration (TGA) for its CT:VQ platform, with the product now officially listed on the Australian Register of Therapeutic Goods. This approval allows the company to roll out CT:VQ commercially across Australia, while advancing its broader growth plans. Unlike traditional ventilation-perfusion imaging methods, CT:VQ produces functional lung assessments from standard non-contrast CT scans, removing the need for radioactive tracers, contrast injections and specialised nuclear medicine equipment.Global Market Expansion Supports the Growth OutlookThe latest Australian approval further broadens CT:VQ international reach, complementing existing regulatory clearances in the United States, the European Union, the United Kingdom, Canada, and New Zealand. The technology has already gained traction at several leading healthcare institutions in the United States, while a commercial partnership with SimonMed Imaging highlights its suitability for large outpatient imaging networks. These developments continue to strengthen the company's global commercial footprint and broaden future revenue opportunities.Will the Next Catalyst Keep the Momentum Alive?The company is now preparing to seek Medicare Benefits Schedule (MBS) reimbursement through the Medical Services Advisory Committee (MSAC), a move that could improve commercial adoption across Australia's healthcare system. With more than 74 CT scanners per million people, Australia provides favourable infrastructure for widespread deployment. As regulatory approvals continue to expand, institutional participation increases and reimbursement efforts advance, investors will be watching closely to see whether these milestones can support stronger commercial performance and drive the next phase of share price momentum.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au